Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASET-JAPAN: Prasugrel Monotherapy After PCI
NCT05117866Active, not recruiting
- Sponsor
- Meditrix
- Start
- Sep 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Open-label, single-arm trial of prasugrel in Chronic Coronary Syndrome (CCS) and non-ST elevation acute coronary syndrome (NSTE-ACS), sponsored by Meditrix. Primary endpoints: Rate of Primary Ischemic Endpoint events (CCS) at 3 months, Rate of Primary Ischemic Endpoint events (NSTE-ACS) at 12 months and 2 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
prasugrel
03
Conditions
Chronic Coronary Syndrome (CCS)non-ST elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on NCT05117866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117866.